医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

New Promega NanoBRET™ Technology Enables Real-Time Monitoring of Protein Interactions in Live Cells

2015年05月05日 PM10:00
このエントリーをはてなブックマークに追加


 

MADISON, Wis.

Promega Corporation announces the launch of NanoBRET™ Protein Interaction Assays, which use a new Bioluminescence Resonance Energy Transfer (BRET) technology that enables scientists to quantitatively measure protein:protein interactions in live cells.

Promega NanoBRET(TM) Protein Interaction Assays use new Bioluminescence Resonance Energy Transfer (B ...

Promega NanoBRET(TM) Protein Interaction Assays use new Bioluminescence Resonance Energy Transfer (BRET) technology that enables scientists to quantitatively measure protein:protein interactions in live cells. (Photo: Business Wire)

Traditional methods for studying interactions between proteins are commonly performed in vitro using only protein fragments and do not provide data in the context of the cellular environment. With NanoBRET Protein Interaction Assays, researchers can study both induction and inhibition of protein interactions in real time using full-length proteins expressed at physiologically relevant levels.

Conventional BRET measures the interaction of proteins using a bioluminescent donor fused to a protein of interest and a fluorescent acceptor fused to its binding partner; the donor does not excite the fluorophore using light, but transfers resonance energy through dipole-dipole coupling. The optimized NanoBRET Protein Interaction Assays use NanoLuc® Luciferase as the energy donor and HaloTag® protein as the energy acceptor. NanoBRET Technology has improved spectral overlap, increased signal, and lower background, providing researchers with a reproducible method for monitoring and screening protein interactions. In addition, the brighter light output from NanoLuc enables use of NanoBRET even at low expression levels, while still providing efficient energy transfer.

To learn more about NanoBRET™ Protein Interaction Assays visit: http://www.promega.com/NanoBRET-PPItechnology

Promega Corporation is a leader in providing innovative solutions and technical support to the life sciences industry. The company’s 3,000 products enable scientists worldwide to advance their knowledge in genomics, proteomics, cellular analysis, drug discovery and human identification. Founded in 1978, the company is headquartered in Madison, WI, USA with branches in 16 countries and over 50 global distributors. For more information about Promega, visit www.promega.com.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150505005084/en/

CONTACT

Promega Corporation
Penny Patterson
Sr. Director,
Communications
Phone: (608) 274-4330
E-mail: penny.patterson@promega.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-301の第I相中間データを発表
  • Intercell USA Changes Name to Valneva USA, Inc. and Expands Commercial Presence
  • ADC Therapeutics präsentiert Zwischenergebnisse aus Phase-I-Studie zu neuartigem Antikörper-Wirkstoff-Konjugat ADCT-402
  • Bertin与Zymo Research宣布达成新的合作